Published in J Biol Chem on October 10, 2006
CCK causes PKD1 activation in pancreatic acini by signaling through PKC-delta and PKC-independent pathways. Biochim Biophys Acta (2006) 1.20
Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther (2009) 1.12
Gastrointestinal growth factors and hormones have divergent effects on Akt activation. Cell Signal (2009) 0.92
PKCθ activation in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters and growth factors is needed for stimulation of numerous important cellular signaling cascades. Biochim Biophys Acta (2011) 0.78
Palmitoylation regulates the intracellular trafficking and stability of c-Met. Oncotarget (2016) 0.77
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol (2010) 2.18
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas (2010) 2.13
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer (2008) 2.11
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem (2008) 1.81
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst (2008) 1.71
Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg (2011) 1.71
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg (2003) 1.70
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res (2004) 1.70
Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol (2005) 1.65
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery (2003) 1.64
Optimization of recovery of RNA from formalin-fixed, paraffin-embedded tissue. Diagn Mol Pathol (2006) 1.63
Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology (2002) 1.62
Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg (2012) 1.55
Partial hepatectomy induces mobilization of a unique population of haematopoietic progenitor cells in human healthy liver donors. J Hepatol (2005) 1.54
Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg (2004) 1.45
Better Survival But Changing Causes of Death in Patients With Multiple Endocrine Neoplasia Type 1. Ann Surg (2015) 1.44
Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol (2014) 1.39
Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) (2004) 1.39
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (2008) 1.33
Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc (2010) 1.33
Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) (2006) 1.30
Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (2003) 1.28
Surgery increases survival in patients with gastrinoma. Ann Surg (2006) 1.26
Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep (2010) 1.23
CCK causes PKD1 activation in pancreatic acini by signaling through PKC-delta and PKC-independent pathways. Biochim Biophys Acta (2006) 1.20
Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg (2004) 1.20
Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg (2003) 1.20
Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer (2002) 1.16
Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc (2011) 1.15
Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes (2008) 1.14
A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl (2008) 1.13
Quantitative immunohistochemistry by measuring cumulative signal strength accurately measures receptor number. J Histochem Cytochem (2003) 1.11
Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res (2002) 1.10
The human trithorax protein hASH2 functions as an oncoprotein. Cancer Res (2008) 1.08
VIP as a trophic factor in the CNS and cancer cells. Peptides (2003) 1.08
Cholecystokinin-stimulated protein kinase C-delta kinase activation, tyrosine phosphorylation, and translocation are mediated by Src tyrosine kinases in pancreatic acinar cells. J Biol Chem (2003) 1.06
Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep (2004) 1.06
Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci (2008) 1.04
Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des (2003) 1.03
Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.02
Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood (2011) 1.00
Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) (2013) 1.00
Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch (2010) 0.99
Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci (2007) 0.99
Transfer and multiplex immunoblotting of a paraffin embedded tissue. Proteomics (2006) 0.98
Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 77427 inhibits tumor growth in vitro and in vivo. Oncogene (2005) 0.98
Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg (2008) 0.98
VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr Opin Endocrinol Diabetes Obes (2011) 0.98
Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery (2003) 0.97
Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Crit Care (2010) 0.96
A multiplex tissue immunoblotting assay for proteomic profiling: a pilot study of the normal to tumor transition of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 0.96
Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells. Eur J Pharmacol (2010) 0.95
Patients with multiple endocrine neoplasia type 1 with gastrinomas have an increased risk of severe esophageal disease including stricture and the premalignant condition, Barrett's esophagus. J Clin Endocrinol Metab (2005) 0.95
Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem (2007) 0.95
Neurally mediated airway constriction in human and other species: a comparative study using precision-cut lung slices (PCLS). PLoS One (2012) 0.94
Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides (2009) 0.94
Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol (2007) 0.94
A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab (2008) 0.93
Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep (2005) 0.93
Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol (2003) 0.93
Bombesin receptor-mediated imaging and cytotoxicity: review and current status. Curr Drug Deliv (2011) 0.93
Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol (2012) 0.93
Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clin Cancer Res (2005) 0.92
Gastrointestinal growth factors and hormones have divergent effects on Akt activation. Cell Signal (2009) 0.92
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol (2012) 0.92
Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg (2007) 0.92
Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw (2006) 0.92
Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab (2004) 0.91
The Src family kinase, Lyn, is activated in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters and growth factors which stimulate its association with numerous other signaling molecules. Biochim Biophys Acta (2006) 0.91
Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem (2004) 0.91
Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts. Mol Imaging Biol (2002) 0.91
Management and outcome of patients with sporadic gastrinoma arising in the duodenum. Ann Surg (2003) 0.90
Molecular basis of the selectivity of gastrin-releasing peptide receptor for gastrin-releasing peptide. Mol Pharmacol (2002) 0.90
Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors. J Pharmacol Exp Ther (2002) 0.90